Market news

NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...

NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. Chief Executive Officer Frank Leonard said the company, founded more th

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

BAAR, Switzerland, September 02, 2026--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.

NovoCure (NVCR) stock dips as the company discloses that a cybersecurity breach exposed limited patient and employee data. Read more here.

The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

NovoCure (NVCR) drew fresh investor attention after raising its 2026 net revenue guidance to a range of US$710 million to US$725 million, following a quarter of record sales and active patient growth. See our latest analysis for NovoCure. The recent guidance upgrade and record quarter come after a sharp swing in sentiment around NovoCure, with the stock gaining 41.54% on a 3 month share price return and 46.59% on a 1 year total shareholder return. However, longer term total shareholder...

NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.

Moby summary of NovoCure Limited's Q2 2026 earnings call

NovoCure (NVCR) has an average rating of overweight and mean price target of $27.14, according to an

Detailed price information for Novocure Ltd Ord Sh (NVCR-Q) from The Globe and Mail including charting and trades.

Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval for its brain therapy candidate. In intra-day trading, the stock climbed to a record high of $20.55 before trimming gains to end the session […]

The medical device maker, which develops Tumor Treating Fields (TTFields) therapy for cancer, said Q2 marked its strongest performance to date.

Novocure delivered record quarterly revenue and active patient growth, raised its full-year financial guidance and expanded the commercial reach of Optune Pax with European approval. Key Investor TakeawaysNovocure (NASDAQ:NVCR) reported record second-quarter net revenue of $183.

NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to

NovoCure (NVCR) delivered earnings and revenue surprises of +56.67% and +5.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BAAR, Switzerland, July 23, 2026--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

NovoCure Ltd (NVCR) reports its strongest commercial quarter with significant revenue growth and strategic advancements, despite facing market and regulatory hurdles.

NovoCure: Q2 Earnings Snapshot

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.